,
Projection de l'incidence et de la mortalité par cancer en France métropolitaine en 2017. Rapport technique, vol.80, 2017. ,
,
, Cancer incidence and mortality in France over the 1980-2012 period:solid tumors, Rev Epidemiol Sante Publique, vol.62, pp.95-108, 2014.
,
Estimations de l'incidence départementale des cancers en France métropolitaine 2008-2010. Étude à partir des données des registres des cancers du réseau Francim et des bases de données médico-administratives ,
Superficial bladder tumors, Eur Urol, vol.42, issue.6, pp.533-574, 2002. ,
, Treatments in invasive bladder cancer. Prog Urol, 2003.
Cancer statistics, CA Cancer J Clin, vol.66, pp.7-30, 2016. ,
Occupational exposures to polycyclic aromatic hydrocarbons and respiratory and urinary tract cancers: an updated systematic review and a meta-analysis to, Arch Toxicol, vol.88, pp.1479-90, 2014. ,
Decreasing trend in tobacco-related cancer incidence, United States, J Community Health, vol.40, p.33, 2005. ,
The nassociation between physical activity and bladder cancer: systematic review and meta-analysis, Br J Cancer, vol.110, pp.1862-70, 2014. ,
Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study, BMC Cancer, vol.15, p.720, 2015. ,
CCAFU french national guidelines 2016-2018 on bladder cancer, Prog Urol, vol.27, issue.1, pp.67-91, 2016. ,
Incidence and clinical characteristics of lower urinary tract symptoms as a presenting symptom for patients with newly diagnosed bladder cancer, Int Braz J Urol, vol.40, pp.198-203, 2014. ,
,
, Recommandations en onco-urologie 2013 du CCAFU : Tumeurs de la vessie, Prog Urol, vol.23, pp.105-130, 2013.
Advances in bladder cancer imaging, BMC Med, vol.11, p.104, 2013. ,
Photodynamic diagnosis of non-muscleinvasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data, Eur Urol, vol.64, pp.846-54, 2013. ,
,
, Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?, Eur Urol, vol.69, pp.231-275, 2016.
, EAU Guidelines on Muscleinvasive and Metastatic Bladder Cancer, 2016.
Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial, Eur Urol, vol.58, issue.2, p.90, 2010. ,
,
, Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review, Eur Urol, 2018.
TNM classification of malignant tumors, pp.262-267, 2009. ,
Classification of bladder tumors in 2006, Prog Urol FMC, pp.16-23, 2006. ,
Updated 2016 EAU Guidelines on Muscleinvasive and Metastatic Bladder Cancer, Eur Urol, vol.71, issue.3, pp.462-475, 2017. ,
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis, Oncologist, vol.21, pp.708-723, 2016. ,
, Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration, Eur Urol
Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate, J Urol, vol.191, issue.4, pp.898-906, 2014. ,
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy, Cancer, vol.115, issue.18, pp.4104-4113, 2009. ,
Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma, Clin Genitourin Cancer, vol.14, issue.1, pp.59-65, 2016. ,
Neoadjuvant chemotherapy in the treatment of muscle invasive bladder cancer with mixed histology, Can J Urol, vol.20, issue.2, pp.6690-6695, 2013. ,
Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer, BJU Int, vol.111, issue.8, pp.325-355, 2013. ,
,
, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer, N Engl J Med, vol.349, issue.9, pp.859-66, 2003.
,
, Five-year follow-up of a prospective trial ofradical cystectomy and neoadjuvant chemotherapy: nordic cys-tectomy trial 1, J Urol, vol.155, issue.6, pp.1903-1909, 1996.
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients, J Clin Oncol, vol.19, pp.666-675, 2001. ,
Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann Surg, vol.240, issue.2, pp.205-213, 2004. ,
,
, Complications for radical cystectomy. Impact of the American Society of Anesthesiologists score, Eur Urol, vol.39, pp.79-84, 2001.
Estimated blood loss and transfusion requirements of radical cystectomy, J Urol, vol.166, pp.2151-2154, 2001. ,
,
, Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS®) society recommendations, Clin Nutr, vol.32, pp.879-87, 2013.
Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial, Eur Urol, vol.66, pp.265-72, 2014. ,
Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy, Eur Urol, issue.17, pp.30660-30667, 2017. ,
,
Do initial experience with an enhanced recovery program after surgery (ERAS) improve postoperative outcomes after cystectomy, Prog Urol, 2018. ,
, , vol.28, pp.351-358
Live strong and prosper: the importance of skeletal muscle strength for healthy ageing, Biogerontology, 2016. ,
Physiopathologie de la cachexie et de la sarcopénie, Traité de nutrition clinique, à tous âges de la vie, pp.619-648, 2016. ,
European consensus on definition an diagnosis, Age Ageing, vol.39, pp.412-435, 2010. ,
Definition and classification of cancer cachexia: an international consensus, Lancet Oncol, vol.12, issue.5, pp.489-95, 2011. ,
,
Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image, J Appl Physiol, vol.97, issue.6, pp.2333-2341, 2004. ,
A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care, Appl Physiol Nutr Metab, 2008. ,
Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses, Int J Biochem Cell Biol, vol.45, issue.10, pp.2302-2310, 2013. ,
Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review ,
, Clin Nutr, vol.37, issue.4, pp.1101-1113, 2018.
Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy, Ann Oncol, vol.28, issue.9, pp.2107-2118, 2017. ,
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma, Ann Oncol, vol.21, issue.8, pp.1594-1602, 2010. ,
,
Sarcopenia as a predictor of complications and survival following radical cystectomy, J Urol, issue.6, pp.1714-1734, 2014. ,
,
Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer, vol.120, pp.2910-2918, 2014. ,
Sarcopenia as a Novel Preoperative Prognostic Predictor for Survival in Patients with Bladder Cancer Undergoing Radical Cystectomy, Ann Surg Oncol, vol.23, issue.5, pp.1048-1054, 2016. ,
,
Change in Psoas Muscle Volume as a Predictor of Outcomes in Patients Treated with Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. Bladder Cancer, vol.3, pp.57-63, 2017. ,
Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder. BMC Cancer, vol.17, p.237, 2017. ,
,
, Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer, J Cachexia Sarcopenia Muscle, vol.9, issue.3, pp.505-513, 2018.
Sarcopenia predicts 90-day mortality and postoperative complications after radical cystectomy for bladder cancer, World J Urol, 2018. ,
Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy, J Clin Oncol: Official Journal of the American Society of Clinical Oncology, vol.21, pp.690-696, 2003. ,
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients, J Clin Oncol: Official Journal of the American Society of Clinical Oncology, vol.19, pp.666-675, 2001. ,
Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology, Eur Urol, vol.55, pp.164-74, 2009. ,
A population based assessment of perioperative mortality after cystectomy for bladder cancer, The Journal of urology, vol.182, pp.70-77, 2009. ,
Standardized assessment of complications in a contemporary series of European patients undergoing radical cystectomy, Int J Urol, vol.21, pp.143-152, 2014. ,
, Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration, Eur Urol, vol.48, pp.202-207, 2005.
, EAU Guidelines on Muscleinvasive and Metastatic Bladder Cancer, 2016.
,
, Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study, Lancet Oncol, 2008.
Prognostic Significance of Sarcopenia in Patients with Esophagogastric Junction Cancer or Upper Gastric Cancer, Ann Surg Oncol, vol.24, issue.7, pp.1804-1810, 2017. ,
Sarcopenia as a prognostic factor among patients with stage III melanoma, Ann Surg Oncol, vol.18, pp.3579-3585, 2011. ,
Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study, Int J Clin Oncol, vol.22, pp.136-144, 2016. ,
Sarcopenia as a predictor of complications and survival following radical cystectomy, J Urol, vol.191, pp.1714-1720, 2014. ,
,
, Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancerspecific and all-cause mortality, Cancer, vol.120, pp.2910-2918, 2014.
,
, Sarcopenia as a novel preoperative prognostic predictor for survival in patients with bladder cancer undergoing radical cystectomy, Ann Surg Oncol, vol.23, pp.1048-1054, 2016.
Lower skeletal muscle index and early complications in patients undergoing radical cystectomy for bladder cancer, World J Surg Oncol, vol.12, p.14, 2014. ,
,
Change in Psoas Muscle Volume as a Predictor of Outcomes in Patients Treated with Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. Bladder Cancer, vol.3, pp.57-63, 2017. ,
Definition and classification of cancer cachexia: an international consensus, Lancet Oncol, vol.12, pp.489-495, 2011. ,
,
, Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index, J Clin Oncol, vol.31, pp.1539-1547, 2013.
TNM classification of malignant tumors, International Union Against Cancer, pp.262-267, 2009. ,
Classification of bladder tumors in 2006, Prog Urol FMC, pp.16-23, 2006. ,
,
,
,
New Equation to Estimate Glomerular Filtration Rate for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration), Annals of Internal Medicine, vol.150, issue.9, pp.604-613, 2009. ,
Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann Surg, vol.240, issue.2, pp.205-213, 2004. ,
Sarcopenia predicts 90-day mortality and postoperative complications after radical cystectomy for bladder cancer, World J Urol, 2018. ,
,
, Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer, J Cachexia Sarcopenia Muscle, vol.9, issue.3, pp.505-513, 2018.
,
, de mes chers condisciples, devant l'effigie d'Hippocrate, Je promets et je jure d'être fidèle aux lois de l'Honneur et de la probité dans l'exercice de La Médecine
, Je donnerai mes soins gratuits à l'indigent et n'exigerai jamais un salaire au-dessus de mon travail
, Admis dans l'intérieur des maisons, mes yeux ne verront pas ce qui se passe, ma langue taira les secrets qui me seront confiés et mon état ne servira pas à corrompre les moeurs ni à favoriser le crime
, Je ne permettrai pas que des considérations de religion, de nation, de race, de parti ou de classe sociale viennent s'interposer entre mon Devoir et mon patient
, Je garderai le respect absolu de la vie humaine dès sa conception. Même sous la menace, je n'admettrai pas de faire usage de mes connaissances médicales contre les lois de l'Humanité
, Respectueux et reconnaissant envers les Maîtres, je rendrai à leurs enfants l'instruction que j'ai reçue de leurs pères
, Que les hommes m'accordent leur estime si je suis fidèle à mes promesses, Que je sois couvert d'opprobre et méprisé de mes confrères si j'y manque